Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/59989
DC FieldValueLanguage
dc.contributor.authorPerez-Calahorra, Sofíaen_US
dc.contributor.authorLaclaustra, Martinen_US
dc.contributor.authorMarco-Benedi, Victoriaen_US
dc.contributor.authorPinto, Xavieren_US
dc.contributor.authorSánchez-Hernández, Rosaen_US
dc.contributor.authorPlana, Núriaen_US
dc.contributor.authorOrtega, Emilioen_US
dc.contributor.authorFuentes, Franciscoen_US
dc.contributor.authorCiveira, Fernandoen_US
dc.date.accessioned2019-12-29T10:08:24Z-
dc.date.available2019-12-29T10:08:24Z-
dc.date.issued2019en_US
dc.identifier.issn1476-511Xen_US
dc.identifier.otherScopus-
dc.identifier.otherWoS-
dc.identifier.urihttp://hdl.handle.net/10553/59989-
dc.description.abstractBackground: There is no randomized clinical trials with recurrence of atherosclerotic cardiovascular disease (ASCVD) as a major outcome with rosuvastatin. In order to analyze potential differences in the clinical response to atorvastatin and rosuvastatin in secondary ASCVD prevention, we have analyzed the clinical evolution of those subjects of the Dyslipemia Registry of the Spanish Society of Arteriosclerosis (SEA) who at the time of inclusion in the Registry had already suffered an ASCVD. Methods: This observational, retrospective, multicenter, national study was designed to determine potential differences between the use of atorvastatin and rosuvastatin in the ASCVD recurrence. Three different follow-up start-times were performed: time of inclusion in the registry; time of first event if this occurred after 2005, and time of first event without date restriction. Results: Baseline characteristics were similar between treatment groups. Among atorvastatin or rosuvastatin users, 89 recurrences of ASCVD were recorded (21.9%), of which 85.4% were coronary. At the inclusion of the subject in the registry, 345 participants had not suffered a recurrence yet. These 345 subjects accumulated 1050 person-years in a mean follow-up of 3 years. Event rates were 2.73 (95% CI: 1.63, 4.25) cases/100 person-years and 2.34 (95% CI: 1.17, 4.10) cases/100 person-years in the atorvastatin and rosuvastatin groups, respectively. There were no statistically significant differences between the two groups independently of the follow-up start-time. Conclusions: This study does not find differences between high doses of rosuvastatin and atorvastatin in the recurrence of ASCVD, and supports their use as clinically equivalent in secondary prevention of ASCVD.en_US
dc.languageengen_US
dc.relation.ispartofLipids in Health and Diseaseen_US
dc.sourceLipids in Health and Disease [ISSN 1476-511X], v. 18 (216) (Diciembre 2019)en_US
dc.subject320501 Cardiologíaen_US
dc.subject.otherRosuvastatinen_US
dc.subject.otherAtorvastatinen_US
dc.subject.otherSecondary preventionen_US
dc.subject.otherHigh-potent statinen_US
dc.titleComparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrenceen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1186/s12944-019-1153-xen_US
dc.identifier.scopus85076365577-
dc.identifier.isi000510489600001-
dc.contributor.authorscopusid49864143900-
dc.contributor.authorscopusid10046356900-
dc.contributor.authorscopusid57189493797-
dc.contributor.authorscopusid7004430064-
dc.contributor.authorscopusid57203232814-
dc.contributor.authorscopusid22980898600-
dc.contributor.authorscopusid8281845100-
dc.contributor.authorscopusid55650129500-
dc.contributor.authorscopusid35517335700-
dc.identifier.eissn1476-511X-
dc.identifier.issue216-
dc.relation.volume18en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid1403031-
dc.contributor.daisngid576146-
dc.contributor.daisngid2491184-
dc.contributor.daisngid31800930-
dc.contributor.daisngid3549698-
dc.contributor.daisngid335717-
dc.contributor.daisngid511489-
dc.contributor.daisngid32138999-
dc.contributor.daisngid89578-
dc.description.numberofpages6en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Perez-Calahorra, S-
dc.contributor.wosstandardWOS:Laclaustra, M-
dc.contributor.wosstandardWOS:Marco-Benedi, V-
dc.contributor.wosstandardWOS:Pinto, X-
dc.contributor.wosstandardWOS:Sanchez-Hernandez, RM-
dc.contributor.wosstandardWOS:Plana, N-
dc.contributor.wosstandardWOS:Ortega, E-
dc.contributor.wosstandardWOS:Fuentes, F-
dc.contributor.wosstandardWOS:Civeira, F-
dc.date.coverdateDiciembre 2019en_US
dc.identifier.ulpgces
dc.description.sjr0,942
dc.description.jcr2,906
dc.description.sjrqQ1
dc.description.jcrqQ3
dc.description.scieSCIE
item.fulltextCon texto completo-
item.grantfulltextopen-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.orcid0000-0003-4991-7445-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameSanchez Hernández, Rosa María-
Appears in Collections:Artículos
Thumbnail
pdf
Adobe PDF (527,13 kB)
Show simple item record

SCOPUSTM   
Citations

15
checked on Jun 9, 2024

WEB OF SCIENCETM
Citations

18
checked on Jun 9, 2024

Page view(s)

91
checked on Apr 13, 2024

Download(s)

94
checked on Apr 13, 2024

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.